Anacetrapib

Anacetrapib

Anacetrapib (pronounced as "an-a-set-ra-pib") is a cholesterol lowering drug that was developed by Merck & Co. but was discontinued in 2017 due to lack of efficacy.

Etymology

The name "Anacetrapib" is derived from the chemical name of the drug, which is "(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one".

Usage

Anacetrapib was designed to increase high-density lipoprotein (HDL, or "good cholesterol") and decrease low-density lipoprotein (LDL, or "bad cholesterol") in the bloodstream. It works by inhibiting the cholesteryl ester transfer protein (CETP), which is involved in the transfer of cholesterol from HDL to LDL.

Related Terms

• Cholesterol
• High-density lipoprotein
• Low-density lipoprotein
• Cholesteryl ester transfer protein
• Merck & Co.

See Also

• Lipid-lowering agent
• Cardiovascular disease
• Atherosclerosis

External links

• Medical encyclopedia article on Anacetrapib
• Wikipedia's article - Anacetrapib

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski